Suppr超能文献

美国原发性脑肿瘤和其他中枢神经系统肿瘤(2014 - 2018年):临床医生CBTRUS统计报告摘要

Primary brain and other central nervous system tumors in the United States (2014-2018): A summary of the CBTRUS statistical report for clinicians.

作者信息

Low Justin T, Ostrom Quinn T, Cioffi Gino, Neff Corey, Waite Kristin A, Kruchko Carol, Barnholtz-Sloan Jill S

机构信息

The Preston Robert Tisch Brain Tumor Center, Duke University School of Medicine, Durham, North Carolina, USA.

Department of Neurosurgery, Duke University School of Medicine, Durham, North Carolina, USA.

出版信息

Neurooncol Pract. 2022 Feb 22;9(3):165-182. doi: 10.1093/nop/npac015. eCollection 2022 May.

Abstract

BACKGROUND

The Central Brain Tumor Registry of the United States (CBTRUS) contains information on all primary brain and other central nervous system (CNS) tumors diagnosed in the United States (US). Here we summarize the 2021 CBTRUS annual statistical report for clinicians.

METHODS

Incidence survival data are obtained from the Centers for Disease Control's National Program of Cancer Registries (NPCR) and National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program. Survival data are obtained from NPCR. Mortality data are obtained from the National Vital Statistics System. Incidence and mortality rates are age-adjusted using the 2000 US population and presented per 100,000 population.

RESULTS

An annual average of 86,355 cases of primary malignant and nonmalignant CNS tumors were diagnosed over the period 2014-2018, corresponding to an average annual age-adjusted incidence rate of 24.25. The most commonly occurring malignant tumor was glioblastoma (14.3%), and the most common predominately nonmalignant tumor was meningioma (39%). Over the 2014-2018 period, there were 16,606 annual average deaths due to malignant primary CNS tumors, corresponding to an average annual age-adjusted mortality rate of 4.43. In this report we detail key incidence, survival, and mortality statistics for major primary CNS tumor histologies, highlighting relevant differences by age, sex, and race.

CONCLUSIONS

This summary describes the most up to date population-based incidence of primary malignant and nonmalignant brain and other CNS tumors in the US, and mortality and survival for primary malignant tumors and aims to serve as a useful resource for clinicians.

摘要

背景

美国中央脑肿瘤登记处(CBTRUS)包含了在美国诊断出的所有原发性脑肿瘤和其他中枢神经系统(CNS)肿瘤的信息。在此,我们为临床医生总结2021年CBTRUS年度统计报告。

方法

发病率生存数据来自疾病控制中心的国家癌症登记计划(NPCR)和国家癌症研究所的监测、流行病学和最终结果(SEER)计划。生存数据来自NPCR。死亡率数据来自国家生命统计系统。发病率和死亡率使用2000年美国人口进行年龄调整,并按每10万人呈现。

结果

2014 - 2018年期间,每年平均诊断出86,355例原发性恶性和非恶性CNS肿瘤,相应的年龄调整后年发病率平均为24.25。最常见的恶性肿瘤是胶质母细胞瘤(14.3%),最常见的主要非恶性肿瘤是脑膜瘤(39%)。在2014 - 2018年期间,每年平均有16,606人死于原发性恶性CNS肿瘤,相应的年龄调整后年死亡率平均为4.43。在本报告中,我们详细介绍了主要原发性CNS肿瘤组织学类型的关键发病率、生存率和死亡率统计数据,突出了年龄、性别和种族的相关差异。

结论

本总结描述了美国原发性恶性和非恶性脑肿瘤及其他CNS肿瘤的最新基于人群的发病率,以及原发性恶性肿瘤的死亡率和生存率,旨在为临床医生提供有用的资源。

相似文献

10
Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT.
J Neurooncol. 2019 Aug;144(1):53-63. doi: 10.1007/s11060-019-03215-x. Epub 2019 Jun 17.

引用本文的文献

2
Unlocking glioblastoma: breakthroughs in molecular mechanisms and next-generation therapies.
Med Oncol. 2025 Jun 21;42(7):276. doi: 10.1007/s12032-025-02830-1.
3
Rapid detection of brain tumor cells using memristors for biomedical applications.
Mater Today Bio. 2025 May 31;32:101934. doi: 10.1016/j.mtbio.2025.101934. eCollection 2025 Jun.
5
MDPNet: a dual-path parallel fusion network for multi-modal MRI glioma genotyping.
Front Oncol. 2025 May 19;15:1574861. doi: 10.3389/fonc.2025.1574861. eCollection 2025.
7
Radiomics-driven neuro-fuzzy framework for rule generation to enhance explainability in MRI-based brain tumor segmentation.
Front Neuroinform. 2025 Apr 17;19:1550432. doi: 10.3389/fninf.2025.1550432. eCollection 2025.
8
Glioblastoma Tumor Microenvironment and Purinergic Signaling: Implications for Novel Therapies.
Pharmaceuticals (Basel). 2025 Mar 8;18(3):385. doi: 10.3390/ph18030385.
9
Antisecretory factor for treatment of peritumoral edema in glioblastoma patients.
Acta Neurochir (Wien). 2025 Mar 8;167(1):64. doi: 10.1007/s00701-025-06481-z.

本文引用的文献

2
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
3
Long-term trends in glioblastoma survival: implications for historical control groups in clinical trials.
Neurooncol Pract. 2020 Mar;7(2):158-163. doi: 10.1093/nop/npz046. Epub 2019 Oct 1.
4
Pilocytic astrocytomas: where do they belong in cancer reporting?
Neuro Oncol. 2020 Feb 20;22(2):298-300. doi: 10.1093/neuonc/noz202.
9
Primary CNS germ cell tumors in Japan and the United States: an analysis of 4 tumor registries.
Neuro Oncol. 2012 Sep;14(9):1194-200. doi: 10.1093/neuonc/nos155. Epub 2012 Aug 6.
10
Glioblastoma survival in the United States before and during the temozolomide era.
J Neurooncol. 2012 Apr;107(2):359-64. doi: 10.1007/s11060-011-0749-4. Epub 2011 Nov 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验